Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

2010 ◽  
Vol 99 (2) ◽  
pp. 261-272 ◽  
Author(s):  
Hilko Ardon ◽  
Stefaan Van Gool ◽  
Isabel Spencer Lopes ◽  
Wim Maes ◽  
Raf Sciot ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Pilot Study ◽  
Glioblastoma Multiforme ◽  
Primary Treatment ◽  
Newly Diagnosed ◽  
Autologous Dendritic Cell ◽  
Newly Diagnosed Glioblastoma

scholarly journals ATIM-13. ALLOGENEIC TUMOR LYSATE/AUTOLOGOUS DENDRITIC CELL VACCINES IN NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS OF CLINICAL TRIAL MC1272

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi28-vi29 ◽  
Author(s):  
Ian F Parney ◽  
Michael P Gustafson ◽  
Timothy Peterson ◽  
Susan M Steinmetz ◽  
Allan B Dietz
Keyword(s):  
Clinical Trial ◽  
Dendritic Cell ◽  
Newly Diagnosed ◽  
Autologous Dendritic Cell ◽  
Tumor Lysate ◽  
Allogeneic Tumor ◽  
Dendritic Cell Vaccines ◽  
Newly Diagnosed Glioblastoma

scholarly journals CTNI-43. ANLOTINIB COMBINED WITH STUPP REGIMEN IN TREATING PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME: A PHASE II PILOT STUDY

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii52-ii52
Author(s):  
Shuzhen Lai ◽  
Yuanyuan Chen
Keyword(s):  
Pilot Study ◽  
Glioblastoma Multiforme ◽  
Adjuvant Therapy ◽  
Disease Progression ◽  
Phase Ii ◽  
Signal Pathways ◽  
Severe Toxicity ◽  
Newly Diagnosed ◽  
Newly Diagnosed Glioblastoma ◽  
Grade 3

Abstract PURPOSE Anlotinib, an orally multi-target tyrosine kinase inhibitor, inhibits tumor angiogenic and proliferative signal pathways. We performed a phase II trial of anlotinib in combination with the STUPP regimen in patients with newly diagnosed glioblastoma multiforme（GBM）to determine whether the combination therapy would safely improve outcomes in this group of patients. An initial pilot study assessed interim safety and tolerability. METHODS AND MATERIALS Ten newly diagnosed GBM patients were included in this study. All patients received standard radiation of 60 Gy in 30 fractions starting within 4–6 weeks after surgery with concurrent TMZ (daily, 75 mg/m2) and anlotinib (8mg per day, from day 1 to 14, every 3 weeks). After a 4-week break, adjuvant therapy including 6 cycles of TMZ (150–200 mg/m², from day 1 to 5, every 4 weeks) and 8 cycles of anlotinib (8mg per day, from day 1 to 14, every 3 weeks) was given. For patients completing adjuvant therapy, anlotinib alone (8mg per day, from day 1 to 14, every 3 weeks) was administrated until disease progression. RESULTS All patients completed concurrent chemo-radiotherapy without interruption. One patient developed grade 3 weight loss at 56th week and grade 3 presumed radiation-induced cognitive disturbance at 60th week. Fatigue and hypertension were frequently observed during treatment, which potentially be related to the treatment. No severe toxicity was observed in other patients. Up to this writing, none of these patients developed disease progression. CONCLUSION Anlotinib combined with the STUPP regimen is a potential choice for newly diagnosed GBM patients. It is well tolerated and the toxicity is manageable. It’s acceptable to continue enrolling of this Phase II study.

scholarly journals Pilot Study to Explore the Accuracy of Current Prediction Equations in Assessing Energy Needs of Patients with Newly Diagnosed Glioblastoma Multiforme

2016 ◽  
Vol 68 (6) ◽  
pp. 926-934 ◽  
Author(s):  
Rebecca B. Little ◽  
Robert A. Oster ◽  
Betty E. Darnell ◽  
Wendy Demark-Wahnefried ◽  
L. Burt Nabors
Keyword(s):  
Pilot Study ◽  
Glioblastoma Multiforme ◽  
Newly Diagnosed ◽  
Prediction Equations ◽  
Energy Needs ◽  
Newly Diagnosed Glioblastoma
Sign in / Sign up

Export Citation Format

Share Document